Mechanism and kinetics of copper complexes binding to the influenza A M2 channel
D. D. Busath, K. L. McGuire, D. H. Ess, P. Smit, R. G. Harrison, J. T. Hill
Abstract
Copper(II) is known to bind in the influenza virus His37 cluster in the homotetrameric M2 proton channel and block the proton current needed for uncoating. Copper complexes based on iminodiacetate also block the M2 proton channel and show reduced cytotoxicity and zebrafish-embryo toxicity. In voltage-clamp oocyte studies using the ubiquitous amantadine-insensitive M2 S31N variant, the current block showed fast and slow phases in contrast to the single phase found for amantadine block of WT M2. Here we evaluate the mechanism of block by copper adamantyl iminodiacitate (Cu(AMT-IDA)) and copper cyclooctyl iminodiacitate (Cu(CO-IDA)) complexes and address whether the complexes can covalently bind to one or more of the His37 imidazoles. The current traces were fitted to parametrized master equations. The energetics of binding and the rate constants suggest that the first step is copper-complex binding within the channel and the slow step in the current block is the covalent bond formation between copper complex and histidine. Isothermal titration calorimetry (ITC) indicates that a single imidazole binds strongly to the copper complexes. Structural optimization using density functional theory (DFT) reveals that the complexes fit inside the channel and project the Cu(II) towards the His37 cluster allowing one imidazole to form a covalent bond with the Cu(II). Electrophysiology and DFT studies also show that the complexes block the G34E amantadine-resistant mutant in spite of some crowding in the binding site by the glutamates.
02 /Specification & Classification
Click any tag to browse matching papers- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Exploring polycyclic scaffolds as adamantane replacements in M2 channel inhibitors of Influenza A virus
Andreea L. Turcu, Rosana Leiva, … Santiago Vázquez·bioRxiv·Jul 26, 2025
- Antiviral Mechanisms and Preclinical Evaluation of Amantadine Analogs that Continue to Inhibit Influenza A Viruses with M2 S31N-Based Drug Resistance
Ian Tietjen, Daniel Kwan, … Antonios Kolocouris·Antiviral ResearchPeer-reviewed·Feb 11, 2025
- Influenza A M2 Inhibitor Binding Understood through Mechanisms of Excess Proton Stabilization and Channel Dynamics
L. C. Watkins, W. F. DeGrado, G. A. Voth·bioRxiv·Jun 19, 2020
- Influenza A M2 Channel Oligomerization is Sensitive to its Chemical Environment
J. A. Townsend, H. M. Sanders, … M. T. Marty·bioRxiv·May 7, 2021
- Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza
C. Scott, J. Kankanala, … S. Griffin·bioRxiv·Jul 24, 2019
- Activation of the influenza B M2 proton channel (BM2)
Zhi Yue, Jiangbo Wu, … Gregory A. Voth·BiochemistryPeer-reviewed·Nov 3, 2024